

Epidermal Growth Factor Receptor and Bladder Cancer

Urologia Internationalis

48, 365-371

DOI: [10.1159/000282357](https://doi.org/10.1159/000282357)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Increased binding capacity of receptors for the epidermal growth factor in benign thyroid nodules and thyroid malignancies. <i>The Clinical Investigator</i> , 1993, 71, 898-902.	0.6	7
2	Molecular prognostic factors in bladder cancer. <i>World Journal of Urology</i> , 1994, 12, 84-8.	1.2	24
3	c-Jun oncogene expression in transitional cell carcinoma of the urinary bladder. <i>British Journal of Urology</i> , 1994, 74, 757-761.	0.1	36
4	Growth factors in bladder cancer. <i>World Journal of Urology</i> , 1995, 13, 349-55.	1.2	14
5	The Prognostic Role of Alterations of the p53 Tumor Suppressor Gene in Superficial and Advanced Stage Bladder Cancer. <i>Oncology Research and Treatment</i> , 1995, 18, 202-210.	0.8	1
6	Cytokine modulation of epidermal growth factor receptor expression on bladder cancer cells is not a major contributor to the antitumour activity of cytokines. <i>European Journal of Cancer</i> , 1995, 31, 2059-2066.	1.3	11
7	Species comparison of the content and composition of urinary proteins. <i>Food and Chemical Toxicology</i> , 1995, 33, 731-746.	1.8	31
8	Chronic treatment with epidermal growth factor stimulates growth of the urinary tract in the rat. <i>Urological Research</i> , 1996, 24, 15-21.	1.5	16
9	Enhanced gene expression of transforming growth factor- β and c-met in rat urinary bladder cancer. <i>Urological Research</i> , 1996, 24, 55-60.	1.5	17
10	Molecular biology of dissemination in bladder cancer ? laboratory findings and clinical significance. <i>World Journal of Urology</i> , 1996, 14, 190-6.	1.2	3
11	Contractile and cytoskeletal proteins in urinary bladder smooth muscle from rats treated with epidermal growth factor. <i>Urological Research</i> , 1996, 24, 229-234.	1.5	6
12	Oncogene Expression and Amplification in Barrett Adenocarcinoma. <i>International Journal of Surgical Pathology</i> , 1997, 4, 203-211.	0.4	2
13	Epidemiologie und Biologie des Harnblasenkarzinoms. <i>Onkologe</i> , 1997, 3, 218-226.	0.7	0
14	Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer. <i>Urological Research</i> , 1997, 25, 9-17.	1.5	78
15	Binding, internalization and degradation of EGF-dextran conjugates in two human bladder-cancer cell lines. , 1997, 70, 383-389.		10
16	Expression of epidermal growth factor receptor in urinary bladder cancer metastases. , 1998, 76, 189-193.		47
17	Prognostic significance of glutathione S-transferase γ and c-Jun in epithelial ovarian cancers. <i>International Journal of Clinical Oncology</i> , 1998, 3, 281-286.	1.0	2
18	The effects of exogenous epidermal growth factor on the developing urinary tract in rats: a stereological description. <i>Urological Research</i> , 1998, 26, 105-110.	1.5	6

#	ARTICLE	IF	CITATIONS
19	Impact of the Expression of Epidermal Growth Factor, Transforming Growth Factor Alpha, and Epidermal Growth Factor Receptor on the Prognosis of Superficial Bladder Cancer. <i>Urology</i> , 1998, 51, 645-649.	0.5	44
20	Significance of Multi-Drug-Resistant Proteins in Predicting Chemotherapy Response and Prognosis in Epithelial Ovarian Cancer*. <i>Journal of Obstetrics and Gynaecology Research</i> , 1999, 25, 387-394.	0.6	39
21	Pharmacological effects of epidermal growth factor (EGF) with focus on the urinary and gastrointestinal tracts. <i>Apmis</i> , 1999, 107, 5-42.	0.9	12
22	Intravesical Administration of EGF-Dextran Conjugates in Patients with Superficial Bladder Cancer. <i>European Urology</i> , 2000, 38, 584-589.	0.9	10
23	Epidemiology and biology of human urinary bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2000, 126, 575-583.	1.2	21
24	Binding of 125I after administration of 125I-EGF-dextran, 125I-EGF or 125I to human bladder cancer spheroids.. <i>International Journal of Oncology</i> , 2000, 17, 559-64.	1.4	1
25	Profile of epidermal growth factor receptor (EGFr) expression in human malignancies: effects of exposure to EGF and its biological influence on established human tumour cell lines.. <i>International Journal of Molecular Medicine</i> , 2000, 6, 495-500.	1.8	17
26	Cellular processing of 125I- and 111in-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells. <i>Nuclear Medicine and Biology</i> , 2000, 27, 827-835.	0.3	36
27	THE WILLET F. WHITMORE, JR., LECTURESHIP: BLOCKADE OF EPIDERMAL GROWTH FACTOR RECEPTORS AS ANTICANCER THERAPY. <i>Journal of Urology</i> , 2001, 165, 1152-1157.	0.2	15
28	The expression of PAX5 in human transitional cell carcinoma of the bladder: relationship with de-differentiation. <i>BJU International</i> , 2001, 83, 1039-1044.	1.3	26
29	The Expression of Oncoproteins in Transitional Cell Carcinoma: Its Correlation with Pathological Behavior, Cell Cycle and Drug Resistance. <i>Urologia Internationalis</i> , 2002, 69, 46-50.	0.6	10
30	Internalisation and retention of EGF-dextran associated radioactivity in transfected Chinese hamster ovary cells expressing the human EGF-receptor. <i>International Journal of Oncology</i> , 2002, 20, 1057.	1.4	1
31	Clasificaci3n y factores pron3sticos de los tumores epiteliales de vejiga. <i>EMC - Urolog3a</i> , 2002, 34, 1-6.	0.0	0
32	Ras signal transduction in carcinogenesis and progression of bladder cancer: molecular target for treatment?. <i>Urological Research</i> , 2002, 30, 273-281.	1.5	31
33	Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma? a prospective study. <i>Head and Neck</i> , 2003, 25, 864-872.	0.9	165
34	Novel approaches with targeted therapies in bladder cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 46, 85-104.	2.0	113
35	Cellular retention of radioactivity and increased radiation dose. Model experiments with EGF-dextran. <i>Nuclear Medicine and Biology</i> , 2003, 30, 303-315.	0.3	23
36	Evaluation of the Therapeutic Potential of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Preclinical Models of Bladder Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 4874-4884.	3.2	78

#	ARTICLE	IF	CITATIONS
37	131I-recombinant human EGF has antitumor effects against MCF-7 human breast cancer xenografts with low levels of EGFR. <i>Nuclear Medicine and Biology</i> , 2004, 31, 435-440.	0.3	6
38	The Significance of Serum Soluble Intercellular Adhesion Molecule 1 and Transforming Growth Factor I± in Patients With Nasopharyngeal Carcinoma. <i>JAMA Otolaryngology</i> , 2004, 130, 1205.	1.5	13
39	Epidermal growth factor receptor and proliferating cell nuclear antigen expression in urine ThinPrep specimens. <i>Cytopathology</i> , 2005, 16, 303-308.	0.4	7
40	Chemoprevention of lung cancer: concepts and strategies. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 549-565.	1.1	4
41	Clinical Applications for Targeted Therapy in Bladder Cancer. <i>Urologic Clinics of North America</i> , 2005, 32, 239-246.	0.8	10
42	Overexpression of laminin-5 Î²2 chain and its prognostic significance in urothelial carcinoma of urinary bladder: association with expression of cyclooxygenase 2, epidermal growth factor, and human epidermal growth factor 2. <i>Human Pathology</i> , 2005, 36, 522-530.	1.1	40
43	The epidermal growth factor stimulates sphingosine kinase-1 expression and activity in the human mammary carcinoma cell line MCF7. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2005, 1738, 72-81.	1.2	86
44	Chemoprevention of bladder cancer. <i>World Journal of Urology</i> , 2006, 24, 445-472.	1.2	22
45	Developing innovative strategies for advanced transitional cell carcinoma of the bladder. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 83-92.	1.1	4
46	Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 555-568.	1.4	117
48	Small-molecule inhibitors of the human epidermal receptor family. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1829-1842.	1.9	25
49	Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. <i>Molecular Cancer</i> , 2009, 8, 94.	7.9	48
50	A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). <i>Gynecologic Oncology</i> , 2010, 118, 308-312.	0.6	59
51	FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy. <i>PLoS ONE</i> , 2010, 5, e13821.	1.1	258
52	Pathobiology and Chemoprevention of Bladder Cancer. <i>Journal of Oncology</i> , 2011, 2011, 1-23.	0.6	21
53	Exploring molecular genetics of bladder cancer: lessons learned from mouse models. <i>DMM Disease Models and Mechanisms</i> , 2012, 5, 323-32.	1.2	40
54	Restoration of LRIG1 suppresses bladder cancer cell growth by directly targeting EGFR activity. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 101.	3.5	16
55	The Diversity of 68Ga-Based Imaging Agents. <i>Recent Results in Cancer Research</i> , 2013, 194, 101-131.	1.8	11

#	ARTICLE	IF	CITATIONS
56	The Crosstalk of c-MET with Related Receptor Tyrosine Kinases in Urothelial Bladder Cancer. , 0, , .		4
57	Tumor Targeting and Pharmacokinetics of a Near-Infrared Fluorescent-Labeled μ -Opioid Receptor Antagonist Agent, Dmt-Tic-Cy5. <i>Molecular Pharmaceutics</i> , 2016, 13, 534-544.	2.3	13
58	Sleeping beauty: awakening urothelium from its slumber. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 312, F732-F743.	1.3	44
59	Nano-BCG: A Promising Delivery System for Treatment of Human Bladder Cancer. <i>Frontiers in Pharmacology</i> , 2017, 8, 977.	1.6	13
60	ALDOLASE A regulates invasion of bladder cancer cells via E-cadherin-EGFR signaling. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 13694-13705.	1.2	21
61	Diphtheria Toxin Fusion Proteins. <i>Current Topics in Microbiology and Immunology</i> , 1998, 234, 63-81.	0.7	36
62	THE WILLET F. WHITMORE, JR., LECTURESHIP: BLOCKADE OF EPIDERMAL GROWTH FACTOR RECEPTORS AS ANTICANCER THERAPY. <i>Journal of Urology</i> , 2001, , 1152-1157.	0.2	2
63	The Potential of EGFR-Targeted Agents in Cancer Prevention. , 2004, , 317-324.		1
64	Molecular Biology and Bladder Cancer. , 1994, , 19-45.		1
66	Radiolabeled Peptide Probes for Liver Cancer Imaging. <i>Current Medicinal Chemistry</i> , 2020, 27, 6968-6986.	1.2	8
68	Chronic systemic treatment with epidermal growth factor in pigs causes pronounced urothelial growth with accumulation of glycoconjugates. <i>American Journal of Pathology</i> , 1995, 147, 1330-8.	1.9	10
69	Targeted therapies in the management of metastatic bladder cancer. <i>Biologics: Targets and Therapy</i> , 2007, 1, 393-406.	3.0	8
70	Analysis of and genes in patients with bladder cancer. <i>Medical Journal of the Islamic Republic of Iran</i> , 2020, 34, 108.	0.9	1
72	TFAP2C Knockdown Sensitizes Bladder Cancer Cells to Cisplatin Treatment via Regulation of EGFR and NF- κ B. <i>Cancers</i> , 2022, 14, 4809.	1.7	6